MarketCapExport financials
INmune Bio (INMB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
INmune Bio Balance Sheet 2025-2011 | INMB
Brief overview of INmune Bio's financial position
The comparison uses five available annual reports from the 2021–2025 interval.
The asset base decreased -67.6%, from $99.9 million to $32.4 million. Resources became smaller over the five periods.
Asset growth of -67.6% came with a -55.2% rise in liabilities. Financial leverage became more prominent.
Equity funds 72.7% of assets versus 80.3% initially. This creates a conservative balance sheet structure.
Net debt moved below zero to -$23.7 million, reflecting surplus cash over debt.
The cash reserve occupies 76.5% of the balance sheet, previously 74.9%. It is one marker of short-term resilience.
The accumulated result is -$209 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
The balance sheet gives no single signal for INmune Bio: some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet INmune Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-23.7 M | -5.78 M | -35.3 M | -42.4 M | -74 M | -21.8 M | -6.83 M | -186 K | -1.37 M | 208 K | - | - | - | - | - |
Long Term Debt |
411 K | 15 M | 397 K | 9.7 M | 704 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
623 K | 140 K | 119 K | 87 K | 72 K | 33.9 K | 8.29 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 126 K | 160 K | - | - | - | - | - | - | - | - |
Total Current Liabilities |
8.42 M | 7.22 M | 18.5 M | 10.9 M | 4.36 M | 1.78 M | 700 K | - | - | - | - | - | - | - | - |
Total Liabilities |
8.83 M | 7.46 M | 18.9 M | 21.7 M | 19.7 M | 1.9 M | 861 K | 824 K | 310 K | 601 K | - | - | - | - | - |
Retained Earnings |
-209 M | -163 M | -121 M | -91 M | -63.7 M | -33.4 M | -21.3 M | -13.6 M | -1.16 M | -326 K | - | - | - | - | - |
Total Assets |
32.4 M | 39.6 M | 57 M | 81.8 M | 99.9 M | 40.7 M | 24.5 M | 17.4 M | 18.4 M | 452 K | - | - | - | - | - |
Cash and Cash Equivalents |
24.8 M | 20.9 M | 35.8 M | 52.2 M | 74.8 M | 22 M | 7 M | 186 K | 1.37 M | - | - | - | - | - | - |
Book Value |
23.5 M | 32.1 M | 38.1 M | 60.1 M | 80.2 M | 38.8 M | 23.6 M | 16.5 M | 18.1 M | -149 K | - | - | - | - | - |
Total Shareholders Equity |
23.5 M | 32.1 M | 37.3 M | 60.1 M | 80.2 M | 38.8 M | 23.6 M | 16.5 M | 18.1 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet INmune Bio
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
593 K | 806 K | 15 M | 15 M | 15 M | 244 K | 284 K | 322 K | - | 397 K | 12.5 M | 15 M | 15 M | 526 K | 15 M | - | 15 M | 704 K | 15 M | 14.3 M | 116 K | 126 K | 126 K | 126 K | 126 K | 160 K | 160 K | 160 K | 160 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.48 M | 6.19 M | 7.98 M | 8.82 M | 8.13 M | 7.46 M | 14.1 M | 15.4 M | - | 18.9 M | 18 M | 19.1 M | 18.7 M | 21.7 M | 20.1 M | - | 18.7 M | 19.7 M | 19.4 M | 17.5 M | 2.31 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 861 K | 861 K | 861 K | 861 K | 824 K | 824 K | 824 K | 824 K | 310 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-216 M | -214 M | -204 M | -197 M | -173 M | -163 M | -154 M | -142 M | - | -121 M | -113 M | -104 M | -97.6 M | -91 M | -85.2 M | - | -70.6 M | -63.7 M | -54 M | -44.6 M | -37.9 M | -33.4 M | -33.4 M | -33.4 M | -33.4 M | -21.3 M | -21.3 M | -21.3 M | -21.3 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -1.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
26.8 M | 25.8 M | 33.4 M | 37.7 M | 37.8 M | 39.6 M | 52.8 M | 52.5 M | - | 57 M | 62.7 M | 69.7 M | 74 M | 81.8 M | 83.8 M | - | 94.4 M | 99.9 M | 108 M | 60.7 M | 65.9 M | 40.7 M | 40.7 M | 40.7 M | 40.7 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | 17.4 M | 17.4 M | 17.4 M | 17.4 M | 18.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
18.4 M | 21.4 M | 27.7 M | 33.4 M | 19.3 M | 20.9 M | 33.6 M | 31.1 M | 26 M | 35.8 M | 41.8 M | 47.8 M | 51 M | 52.2 M | 57.4 M | 61.2 M | 66.7 M | 74.8 M | 84.5 M | 39.5 M | 45.3 M | 22 M | 22 M | 22 M | 22 M | 7 M | 7 M | 7 M | 7 M | 186 K | 186 K | 186 K | 186 K | 1.37 M | - | - | - | 142 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
20.4 M | 19.6 M | 25.4 M | 28.9 M | 29.7 M | 32.1 M | 38.7 M | 37.1 M | - | 38.1 M | 44.7 M | 50.7 M | 55.3 M | 60.1 M | 63.7 M | - | 75.6 M | 80.2 M | 88.3 M | 43.2 M | 63.6 M | 38.8 M | 38.8 M | 38.8 M | 38.8 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 18.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
20.4 M | 19.6 M | 25.4 M | 28.9 M | 29.7 M | 32.1 M | 38.7 M | 36.3 M | 28.2 M | 37.3 M | 43.9 M | 50.7 M | 55.3 M | 60.1 M | 63.7 M | 69.9 M | 75.6 M | 80.2 M | 88.3 M | 43.2 M | 63.6 M | 38.8 M | 38.8 M | 38.8 M | 38.8 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 18.1 M | - | - | - | -149 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of INmune Bio, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
- | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M | Britain |